<?xml version='1.0' encoding='utf-8'?>
<document id="25600613"><sentence text="In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure."><entity charOffset="79-89" id="DDI-PubMed.25600613.s1.e0" text="tacrolimus" /><entity charOffset="91-96" id="DDI-PubMed.25600613.s1.e1" text="FK506" /><pair ddi="false" e1="DDI-PubMed.25600613.s1.e0" e2="DDI-PubMed.25600613.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25600613.s1.e0" e2="DDI-PubMed.25600613.s1.e1" /></sentence><sentence text="The effect of concomitant drugs having a cytochrome P450 (CYP) 3A inhibitory potency on tacrolimus exposure was predicted from in vitro metabolism results"><entity charOffset="88-98" id="DDI-PubMed.25600613.s2.e0" text="tacrolimus" /></sentence><sentence text=" In this study, the IC₅₀ values of concomitant drugs on the formation of M-I, the major metabolite of tacrolimus, were determined, and the effect on oral exposure (AUCp"><entity charOffset="102-112" id="DDI-PubMed.25600613.s3.e0" text="tacrolimus" /></sentence><sentence text="o" /><sentence text=") of tacrolimus was assessed from static models"><entity charOffset="5-15" id="DDI-PubMed.25600613.s5.e0" text="tacrolimus" /></sentence><sentence text=" When an absorbed fraction (Fa ) of 0" /><sentence text="97, intestinal wall availability (Fg) of 0" /><sentence text="27 and fraction metabolized by CYP3A (fm(CYP3A)) of 0" /><sentence text="8 were used, the least bias was observed for the prediction of the AUCp" /><sentence text="o" /><sentence text=" of tacrolimus"><entity charOffset="4-14" id="DDI-PubMed.25600613.s11.e0" text="tacrolimus" /></sentence><sentence text=" The relationship of the IC₅₀ values of 11 inhibitors between tacrolimus and typical CYP3A substrates (midazolam and testosterone) was also analysed"><entity charOffset="62-72" id="DDI-PubMed.25600613.s12.e0" text="tacrolimus" /><entity charOffset="103-112" id="DDI-PubMed.25600613.s12.e1" text="midazolam" /><entity charOffset="117-129" id="DDI-PubMed.25600613.s12.e2" text="testosterone" /><pair ddi="false" e1="DDI-PubMed.25600613.s12.e0" e2="DDI-PubMed.25600613.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25600613.s12.e0" e2="DDI-PubMed.25600613.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25600613.s12.e0" e2="DDI-PubMed.25600613.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25600613.s12.e1" e2="DDI-PubMed.25600613.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25600613.s12.e1" e2="DDI-PubMed.25600613.s12.e2" /></sentence><sentence text=" A strong correlation was found between the IC₅₀ values of tacrolimus and typical CYP3A substrates (r(2)  ≥ 0"><entity charOffset="59-69" id="DDI-PubMed.25600613.s13.e0" text="tacrolimus" /></sentence><sentence text="85)" /><sentence text=" The predictability of the effect of inhibitors on tacrolimus AUCp" /><sentence text="o" /><sentence text=" was investigated based on the same static models with the use of published IC₅₀ values for midazolam and testosterone"><entity charOffset="92-101" id="DDI-PubMed.25600613.s17.e0" text="midazolam" /><entity charOffset="106-118" id="DDI-PubMed.25600613.s17.e1" text="testosterone" /><pair ddi="false" e1="DDI-PubMed.25600613.s17.e0" e2="DDI-PubMed.25600613.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25600613.s17.e0" e2="DDI-PubMed.25600613.s17.e1" /></sentence><sentence text=" The bias for the prediction of tacrolimus AUCp"><entity charOffset="32-42" id="DDI-PubMed.25600613.s18.e0" text="tacrolimus" /></sentence><sentence text="o" /><sentence text=" was minimal with the use of IC₅₀ values determined using tacrolimus itself as a substrate"><entity charOffset="58-68" id="DDI-PubMed.25600613.s20.e0" text="tacrolimus" /></sentence><sentence text=" These results suggest that tacrolimus itself is still the best choice for predicting the AUCp"><entity charOffset="28-38" id="DDI-PubMed.25600613.s21.e0" text="tacrolimus" /></sentence><sentence text="o" /><sentence text=" of tacrolimus, although our findings suggest that midazolam or testosterone may be used instead of tacrolimus to estimate roughly (predicted AUCp"><entity charOffset="4-14" id="DDI-PubMed.25600613.s23.e0" text="tacrolimus" /><entity charOffset="51-60" id="DDI-PubMed.25600613.s23.e1" text="midazolam" /><entity charOffset="64-76" id="DDI-PubMed.25600613.s23.e2" text="testosterone" /><entity charOffset="100-110" id="DDI-PubMed.25600613.s23.e3" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e0" e2="DDI-PubMed.25600613.s23.e0" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e0" e2="DDI-PubMed.25600613.s23.e1" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e0" e2="DDI-PubMed.25600613.s23.e2" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e0" e2="DDI-PubMed.25600613.s23.e3" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e1" e2="DDI-PubMed.25600613.s23.e1" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e1" e2="DDI-PubMed.25600613.s23.e2" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e1" e2="DDI-PubMed.25600613.s23.e3" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e2" e2="DDI-PubMed.25600613.s23.e2" /><pair ddi="false" e1="DDI-PubMed.25600613.s23.e2" e2="DDI-PubMed.25600613.s23.e3" /></sentence><sentence text="o" /><sentence text=" within an approximately 2-fold range of observed values) the effect of CYP3A inhibitors on the tacrolimus AUCp" /><sentence text="o" /><sentence text="" /></document>